Emma Reeve
CIK 1680329 · Chief Financial Officer · last filed 2026-06-15
Emma Reeve is a Chief Financial Officer who has filed 56 SEC Form 4 insider transactions across 6 companies since 2016. The most recent filing, for WHWK, was dated Jun 15, 2026. Across all open-market trades the lifetime net is −$10.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $624.8K across reported positions. 10 Form 144 notices of planned sales are also on file; the latest, for PTCT on Jan 5, 2026, lists the filer as a director.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTCT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
195 WEST STREET
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WHWK | Director | — | $3.13 | — | $0 | 2 | 2026-06-15 |
| PTCT | Director | 10,666 | $58.58 | $624.8K | -$6.12M | 18 | 2026-01-06 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | — | $2.05 | — | $0 | 4 | 2024-06-14 |
| EDIT | Director | — | $1.77 | — | $0 | 4 | 2024-06-03 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Chief Financial Officer | 6,260 | $33.99 | $212.8K | -$4.16M | 16 | 2021-02-23 |
| PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Corp. VP & Interim CFO | 8,468 | — | — | $0 | 1 | 2016-12-09 |
10b5-1 Trading Plans
1 plan · 1 in force| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| PTCT Director |
Mar 4, 2025 | Jun 2, 2025 | Feb 26, 2027 | 85,733 shares | 75,733 (88%) last filed Jan 6, 2026 |
Active | 10-Q |
Recent Filings
56 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-15 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | PTCT | Mixed10b5-1 Plan adopted Mar 4, 2025 |
+4,000 | -$21.6K | EDGAR |
| 2026-01-05 | PTCT | Notice (144) Director · Planned Jan 5, 2026 · 10b5-1 plan Sold: Form 4 filed Jan 6, 2026 |
−734 | -$55.8K | EDGAR |
| 2025-12-05 | PTCT | Mixed10b5-1 Plan adopted Mar 4, 2025 |
— | -$23.5K | EDGAR |
| 2025-12-03 | PTCT | Notice (144) Director · Planned Dec 3, 2025 · 10b5-1 plan Sold: Form 4 filed Dec 5, 2025 |
−733 | -$57.6K | EDGAR |
| 2025-11-25 | PTCT | Mixed10b5-1 Plan adopted Mar 4, 2025 |
— | -$283.4K | EDGAR |
| 2025-11-21 | PTCT | Notice (144) Director · Planned Nov 21, 2025 · 10b5-1 plan Sold: Form 4 filed Nov 25, 2025 |
−10,000 | -$795.0K | EDGAR |
| 2025-11-14 | PTCT | Mixed10b5-1 Plan adopted Mar 4, 2025 |
— | -$205.0K | EDGAR |
| 2025-11-12 | PTCT | Notice (144) Director · Planned Nov 12, 2025 · 10b5-1 plan Sold: Form 4 filed Nov 14, 2025 |
−7,333 | -$546.3K | EDGAR |
| 2025-10-31 | PTCT | Mixed10b5-1 Plan adopted Mar 4, 2025 |
−3,666 | -$631.6K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).